3D rendition of T cells attacking cancer cells. Credit: La Jolla Institute for Immunology
Researchers uncover a new strategy to avoid cancer immunotherapy side effects. It’s not often that a failed clinical trial leads to a scientific breakthrough.
When patients in the UK started experiencing negative side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back, examined the data, and worked with patient samples to determine what went wrong.
Their findings, published today (May 4, 2022) in the journal Nature, provide critical clues to why many immunotherapies trigger dangerous side effects—and point to a more effective strategy for treating patients with solid tumors.
When patients in the UK started experiencing negative side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back, examined the data, and worked with patient samples to determine what went wrong.
Their findings, published today (May 4, 2022) in the journal Nature, provide critical clues to why many immunotherapies trigger dangerous side effects—and point to a more effective strategy for treating patients with solid tumors.
“This work shows the importance of learning from early stage clinical trials,” says La Jolla Institute for Immunology (LJI) Professor Pandurangan Vijayanand, M.D., Ph.D., who co-led the new research with Christian H. Ottensmeier, M.D., Ph.D., FRCP, a professor with the University of Liverpool, The Clatterbridge Cancer Centre NHS Foundation Trust, and adjunct professor at LJI. READ MORE...
